Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.

@article{Moroni2014RituximabVM,
  title={Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.},
  author={Gabriella Moroni and Francesca Raffiotta and Barbara Trezzi and Elisa Giglio and Nicoletta Mezzina and Nicoletta Del Papa and Pier Luigi Meroni and Piergiorgio Messa and Alberto Renato Sinico},
  journal={Rheumatology},
  year={2014},
  volume={53 9},
  pages={1570-7}
}
OBJECTIVE We report the first comparison between rituximab (RTX) and either MMF or CYC pulses in the treatment of active LN. METHODS Fifty-four patients with active LN received three methylprednisolone pulses for 3 consecutive days followed by oral prednisone and RTX 1 g at days 3 and 18 (17 patients) or MMF 2-2.5 g/day (17 patients) or six CYC pulses (0.5 g every fortnight) (20 patients). At 4 months MMF, AZA or ciclosporin were associated to prednisone as a consolidation/maintenance therapy… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 16 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…